Lupinem

Cilastatin is a renal dehydropeptidase inhibitor that lacks intrinsic antibacterial activity but is used exclusively in fixed-ratio combination with the carbapenem antibiotic imipenem to treat serious bacterial infections by preventing the enzymatic degradation of imipenem in the kidneys.[1][2] This combination, marketed as Primaxin, was first approved by the U.S. Food and Drug Administration in 1985 and has since become a cornerstone therapy for multidrug-resistant infections.[3][2]